Editorial / about this board
About Medicinal TB-500.
A status board that sorts the published TB-500 and thymosin beta-4 research into cited, tiered rows. No clinic, no vendor, no prescriptions.
What this site is
Medicinal TB-500 is a status board for the peer-reviewed research on TB-500 and its parent protein, thymosin beta-4. It is not a clinic and staffs no clinicians; it gives no medical advice, and it makes, sells, and distributes nothing. Its work is to read the published science and sort each finding, cited, onto the board.
The site is built as a flat status board: each finding is sorted by evidence tier — structural, preclinical, human-data, or no-human-data — and cited to its source. That structure exists because the TB-500 record demands it. Most efficacy research was run on full-length thymosin beta-4, not the Ac-LKKTETQ seven-mer that is sold and detected as TB-500, and a board that tags each card by molecule and evidence tier is the honest way to present a compound whose story is animal promise, scarce human data, and a standing identity caveat.
What "medicinal" means here
The word "medicinal" in this site's name is editorial framing, not a claim about services. It marks the register we read the literature in — who studies this peptide, what it is studied for, and where it stands in the regulatory landscape — not an offer of treatment, consultation, or prescription. We do not run a pharmacy and we do not facilitate access to any substance.
That framing is why the TB-500 legal status page is a first-class part of the board rather than a footnote. The present-tense regulatory record — a 503A Category 2 placement whose nomination was later withdrawn, no FDA approval, a WADA prohibition, and a July 2026 compounding-review meeting with no published outcome — is reported from primary FDA sources as general information, not as legal or medical advice.
How we handle the evidence
Three rules govern the copy. First, every quantitative claim cites a study, and the citation says which molecule the study used. Second, dosing is reported strictly as research context — what was administered, to which species, by which route, at which dose — never as a human protocol. Third, the gaps are surfaced, not buried: the empty human-trial column for the fragment, the tumor-angiogenesis safety signal, and the non-monotonic and null animal results all get their own status rows.
We describe research findings; we do not recommend doses for humans, and apart from one prescription-access note we do not name vendors, clinics, or telehealth providers. Where the published record is precise, we are precise. Where it is silent, we say so.